Vaccine Production Strain for Acellular Pertussis Vaccine

Available for licensing from the NIH is a vaccine production strain of Bordetella bronchiseptica that produces Bordetella pertussis toxin in high yield. The Bordetella bronchiseptica strain has been modified to eliminate expression of filamentous hemagglutinin, which typically has to be removed in purification of the toxin, thereby reducing the yield of the active vaccine component. Immediately available for licensing is a strain that encodes a mutated pertussis toxin, which does not have to be chemically detoxified.

Potential Commercial Applications:		Competitive Advantages:
Production of Bordatella pertussis toxin for acellular vaccine use.

Inventors:

Tod Merkel (NIDCR)  ➽ more inventions...

Jerry Keith (NIDCR)  ➽ more inventions...

Xiaoming Yang (NIDCR)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 7,101,558 issued 2006-09-05
PCT Application No. PCT/US01/20356
US Application No. 10/312,272

Licensing Contact:
Vladimir Knezevic, M.D.
Email: vlado.knezevic@nih.gov
Phone: 301.443.5560

OTT Reference No: E-159-1999-0
Updated: Sep 16, 2015